FDA Regulatory Agenda Includes “Complete Response” Rule, E-Drug Listing
Executive Summary
A notice of proposed rulemaking for FDA's "complete response" regulation is scheduled for publication in July, according to HHS' semiannual regulatory agenda published in the June 28 Federal Register
You may also be interested in...
FDA 2004 Reg Agenda Includes CFC Albuterol Phase Out, Final Label Rule
FDA will begin the phase out of CFC-containing albuterol products during 2004, according to HHS' semiannual regulatory agenda published in the Dec. 22 Federal Register
FDA Investor Relations: SEC Agreement Close, “Complete Response” Reg Not
FDA's role in policing investor communications about regulatory actions will continue to receive attention in 2004 after the Securities & Exchange Commission opened investigations into Biopure and Amylin
FDA Investigational Drug Export Rule Encourages IND, Requires Certification
Firms exporting investigational drugs may want to obtain INDs for the products even though the designation is not required, FDA said in a 1proposed rule published in the Federal Register June 19